Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|September 2, 2018
Patheon, part of Thermo Fisher Scientific
Thermo Fisher Scientific provides end-to-end development and manufacturing solutions to customers of all sizes through Patheon and Fisher Clinical Services, which deliver pharma services and clinical trials services.
Advertisement
Thermo Fisher Scientific provides end-to-end development and manufacturing solutions to customers of all sizes through Patheon and Fisher Clinical Services, which deliver pharma services and clinical trials services. With more than 40 locations around the world, the company has extensive capabilities including drug substance and product development, clinical trials, and commercial-scale manufacturing.
4815 Emperor Blvd, Durham, NC 27703-8580
CPhI Worldwide Booth Number: 3D30
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement